Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 720-729

  Mason, John N ^a   Deecher, Darlene C ^b   Richmond, Rhonda L ^a   Stack, Gary ^b   Mahaney, Paige E ^b   Trybulski, Eugene ^b   Winneker, Richard C ^b   Blakely, Randy D ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c MRBIII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DESIPRAMINE; DESVENLAFAXINE; IMIPRAMINE; MAZINDOL; METHYLPHENIDATE; NISOXETINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; RAC[1 [1 (3 CHLORO PHENYL) 2 (4 METHYL PIPERAZIN 1 YL)ETHYL]CYCLOPHEXANOL; SEROTONIN TRANSPORTER; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; WY 46824;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIGAND BINDING; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

BINDING SITES; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELLS, CULTURED; COCAINE; CYCLOHEXANOLS; FLUOXETINE; HUMANS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOLIGAND ASSAY;

EID: 35549013297     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125716     Document Type: Article

References (42)

1. Adkins EM, Barker EL, and Blakely RD (2001) Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol 59:514-523.
2. Alfinito PD, Huselton C, Chen X, and Deecher DC (2006) Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 1098:71-78.
3. Apparsundaram S, Schroeter S, Giovanetti E, and Blakely RD (1998) Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther 287: 744-751.
4. Barker EL, Moore KR, Rakhshan F, and Blakely RD (1999) Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 19:4705-4717.
5. Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, and Blakely RD (1998) High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem 273:19459-19468.
6. Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, and Blakely RD (2000) Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci 20:7571-7578.
7. Blier P (2001) Norepinephrine and selective norepinephrine reuptake inhibitors in depression and mood disorders: their pivotal roles. J Psychiatry Neurosci 26 (Suppl):S1-S2.
8. Bönisch H and Brüss M (2006) The norepinephrine transporter in physiology and disease. Handb Exp Pharmacol 175:485-524.
9. Chen F, Larsen MB, Sanchez C, and Wiborg O (2005) The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15:193-198.
10. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Corman SL, Fedutes BA, and Culley CM (2004) Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 61:2391-2399.
12. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, and Andree TH (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657-665.
13. Dell'Osso B, Nestadt G, Allen A, and Hollander E (2006) Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 67:600-610.
14. Galli A, DeFelice LJ, Duke BJ, Moore KR, and Blakely RD (1995) Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter- transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol 198:2197-2212.
15. Gether U, Andersen PH, Larsson OM, and Schousboe A (2006) Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27:375-383.
16. Gorentla BK and Vaughan RA (2005) Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuropharmacology 49:759-768.
17. Hahn MK, Robertson D, and Blakely RD (2003) A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 23:4470-4478.
18. Hastrup H, Karlin A, and Javitch JA (2001) Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci U S A 98:10055-10060.
19. Henry LK, Defelice LJ, and Blakely RD (2006a) Getting the message across: a recent transporter structure shows the way. Neuron 49:791-796.
20. Henry LK, Field JR, Adkins EM, Parnas ML, Vaughan RA, Zou MF, Newman AH, and Blakely RD (2006b) Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem 281:2012-2023.
21. Husbands GEM and Stack GP (1989a) inventors; American Home Products, assignee. Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols. U.S. Patent 4826844. 1989 May 2.
22. Husbands GEM and Stack GP (1989b) inventors; American Home Products, assignee. Substituted cycloalkanol. U.S. Patent EP310268. 1989 May 2.
23. Keller NR, Diedrich A, Appalsamy M, Miller LC, Caron MG, McDonald MP, Shelton RC, Blakely RD, and Robertson D (2006) Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension. Neuroscience 139:931-946.
24. Keller NR, Diedrich A, Appalsamy M, Tuntrakool S, Lonce S, Finney C, Caron MG, and Robertson D (2004) Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation 110:1191-1196.
25. Keller NR and Robertson D (2006) Familial orthostatic tachycardia. Curr Opin Cardiol 21:173-179.
26. Kilic F and Rudnick G (2000) Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci U S A 97:3106-3111.
27. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
28. Lorang D, Amara SG, and Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14:4903-4914.
29. Miner LH, Jedema HP, Moore FW, Blakely RD, Grace AA, and Sesack SR (2006) Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. J Neurosci 26:1571-1578.
30. Pacholczyk T, Blakely RD, and Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350-354.
31. Plenge P and Mellerup ET (1997) An affinity-modulating site on neuronal monamine transport proteins. Pharmacol Toxicol 80:197-201.
32. 3H] citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol 206:243-250.
33. Schroeder C, Adams F, Boschmann M, Tank J, Haertter S, Diedrich A, Biaggioni I, Luft FC, and Jordan J (2004) Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol 286:R851-R856.
34. Stahl SM, Grady MM, Moret C, and Briley M (2005) SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10:732-747.
35. Sung U, Apparsundaram S, Galli A, Kahlig KM, Savchenko V, Schroeter S, Quick MW, and Blakely RD (2003) A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci 23:1697-1709.
36. Sung U, Jennings JL, Link AJ, and Blakely RD (2005) Proteomic analysis of human norepinephrine transporter complexes reveals associations with protein phosphatase 2A anchoring subunit and 14-3-3 proteins. Biochem Biophys Res Commun 333:671-678.
37. Than C, Morimoto H, Andreas H, and Williams PG (1995) Preparation, NMR characterization, and labeling reactions of tritiated borane-THF complex at high specific radioactivity. J Org Chem 60:7503-7507.
38. Torres GE, Yao WD, Mohn RR, Quan H, Kim K, Levey AI, Staudinger J, and Caron MG (2001) Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30:121-134.
39. Usera PC, Vincent S, and Robertson D (2004) Human phenotypes and animal knockout models of genetic autonomic disorders. J Biomed Sci 11:4-10.
40. Vis PM, van Baardewijk M, and Einarson TR (2005) Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 39:1798-1807.
41. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, and Caron MG (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3:465-471.
42. +/Cl-dependent neurotransmitter transporters. Nature 437:215-223.